Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN41194621]

Table 6 Changes in alkaline phosphatase at different time points

	3–6 months		1 year		2 years		3 years
Number of patients and change in alkaline
phosphatase	Active	Placebo	Active	Placebo	Active	Placebo	Active	Placebo
n	694	721	558	595	444	473	360	362
Decrease ≥ 20%	81.0	3.1	72.8	5.1	76.4	11.0	87.5	21.3
Decrease 0–20%	15.9	44.1	21.7	37.2	19.4	40.9	8.9	43.2
Increase	3.2	52.8	5.6	57.7	4.3	48.1	3.6	35.5

Percentage changes in alkaline phosphatase by treatment group between baseline and 3–6 months, and 1, 2 and 3 years, as a measure of compliance.

ISSN: 1745-6215